Glypican 3

What is the Glypican Serum test?

The Glypican Serum test is a diagnostic blood test used to measure the levels of glypicans, a family of heparan sulfate proteoglycans that play a critical role in cell growth, differentiation, and signaling pathways. Glypicans are particularly important in developmental biology and have been linked to certain cancers, including hepatocellular carcinoma. This test is often used in research and clinical settings to assess tumor markers and developmental disorders.


Why is this test performed?

Doctors may recommend this test to evaluate glypican expression in cases of suspected liver cancer, neurological disorders, or congenital abnormalities. Since glypicans are involved in cell signaling and tumor growth, abnormal levels could indicate the presence of malignancies or developmental defects. This test can also be used as part of a broader cancer screening panel or in monitoring disease progression.


How is the Glypican Serum test conducted?

A blood sample is drawn from a vein in the patient's arm and analyzed using laboratory techniques to measure glypican levels. The test requires no special preparation, although patients should inform their doctors about any medications they are taking, as certain drugs might interfere with results. The processing time for results varies but is typically available within a few days.


What do abnormal results indicate?

Elevated glypican levels can be associated with hepatocellular carcinoma, certain neurological disorders, and developmental abnormalities. In contrast, low levels may not necessarily indicate a disease but could be of interest in research settings. Since glypicans are involved in cancer biology, an abnormal result usually necessitates further testing to determine the exact cause.


What are the next steps if results are abnormal?

If the test shows abnormal glypican levels, the doctor may recommend additional diagnostic procedures such as imaging studies, biopsies, or genetic testing to confirm a diagnosis. Treatment options will depend on the underlying condition, ranging from cancer therapies to targeted treatments for developmental disorders. Follow-up testing may also be required to monitor changes in glypican levels over time.